Fig. 1.

Schematic diagram of the experimental protocol. a ROS imaging assessment using autoradiography (ARG) with [³H]hydromethidine (³H-HM) at 1, 2, 5, and 7 h after tMCAO (90 min) in the saline group (n = 7–8 in each time point). b ROS imaging assessment using ARG using ³H-HM at 1, 5, and 7 h after tMCAO (90 min) in the DMTU group (n = 5–8 in each time point). c BBB permeability assessment using contrast enhanced MRI with Gd-DTPA at 1, 5, and 7 h after tMCAO (90 min) in the saline or DMTU group (n = 3–5 at each time point). d Cerebral infarction assessment using T2-MRI and TTC staining at 24 h after tMCAO (90 min) in the saline and DMTU groups (n = 12–13 in each group). Saline or DMTU was injected 30 min before initiation of MCAO. All MRI experiments were performed under isoflurane anesthesia. ADC apparent diffusion coefficient, T2 T2-weighted MR imaging, Gd-DTPA gadolinium diethylenetriaminepentaacetate, TTC 2,3,5-triphenyltetrazolium chloride